Cutpoints in clinical chemistry: time for fundamental reassessment. by Vickers, A, Lilja, H

Editorial comment. by Vickers, A, Lilja, H

Prostate cancer: estimating the benefits of PSA screening. by Vickers, A, Lilja, H

Urological cancer: Time for another rethink on prostate cancer screening. by Vickers, A, Lilja, H

We need a better marker for prostate cancer. How about renaming PSA? by Vickers, A, Lilja, H

Predicting prostate cancer many years before diagnosis: how and why? by Vickers, A, Lilja, H

PSA is dead, long live PSA. by Vickers, A, Lilja, H

Five genetic variants associated with prostate cancer. by Vickers, A, Lilja, H, Scardino, P

Screening for prostate cancer: early detection or overdetection? by Vickers, A, Roobol, M, Lilja, H

Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer. by Lilja, H, Vickers, A, Scardino, P

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. by Lilja, H, Ulmert, D, Vickers, A

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278)) by Lilja, H, Ulmert, D, Vickers, A

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? by Vickers, A, Savage, C, Lilja, H

Screening for prostate cancer. by Carlsson, S, Vickers, A, Lilja, H, Hugosson, J

Screening for prostate cancer: To the editor by Carlsson, S, Vickers, A, Lilja, H, Hugosson, J

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. by Vickers, A, Savage, C, O'Brien, M, Lilja, H

In reply by Vickers, A, Savage, C, O'Brien, F, Lilja, H

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. by Vickers, A, Till, C, Tangen, C, Lilja, H, Thompson, I

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. by Savage, C, Lilja, H, Cronin, A, Ulmert, D, Vickers, A

Systematic review of statistical methods used in molecular marker studies in cancer. by Vickers, A, Jang, K, Sargent, D, Lilja, H, Kattan, M